FIG. 1.
Study flow diagram. Eight patients did not complete the treatment phase. Five patients were withdrawn due to screening laboratory values that emerged only after randomization (five with a positive urine drug screen for cannabinoids and one with elevated liver enzymes). Two individuals in the INH group were withdrawn following hemoptysis. Two patients died during follow-up (for details, see the text).